Related references
Note: Only part of the references are listed.BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Francis H. Glorieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis
Kyu Sang Joeng et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
David G. Little et al.
BONE (2017)
Effects of sclerostin antibodies in animal models of osteoporosis
Michael Stuart Ominsky et al.
BONE (2017)
Sclerostin's role in bone's adaptive response to mechanical loading
Gabriel L. Galea et al.
BONE (2017)
Sclerostin measurement in human disease: Validity and current limitations
Aline G. Costa et al.
BONE (2017)
Hormonal and systemic regulation of sclerostin
Matthew T. Drake et al.
BONE (2017)
Role and mechanism of action of sclerostin in bone
Jesus Delgado-Calle et al.
BONE (2017)
Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2
Makoto Fujiwara et al.
BONE (2016)
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap-/- Mice, a Model of Recessive Osteogenesis Imperfecta
Ingo Grafe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal Women
Sjur Reppe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility
A. Carriero et al.
BONE (2014)
Cartilage Turnover Reflected by Metabolic Processing of Type II Collagen: A Novel Marker of Anabolic Function in Chondrocytes
Natasja Staehr Gudmann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Targeting the LRP5 Pathway Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta
Christina M. Jacobsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Circulating Sclerostin in Children and Young Adults with Heritable Bone Disorders
Telma Palomo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Serum Sclerostin Levels Are Decreased in Adult Patients With Different Types of Osteogenesis Imperfecta
Roland Kocijan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
Eric S. Orwoll et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Ingo Grafel et al.
NATURE MEDICINE (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sclerostin Antibody Improves Skeletal Parameters in a Brtl/+ Mouse Model of Osteogenesis Imperfecta
Benjamin P. Sinder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women
Claire Durosier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading
Xiaolin Tu et al.
BONE (2012)
Association between sclerostin and bone density in chronic spinal cord injury
Leslie R. Morse et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
High Serum Sclerostin Predicts the Occurrence of Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study
Mohammed-Salleh M. Ardawi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Serum Sclerostin and Risk of Hip Fracture in Older Caucasian Women
Aarthi Arasu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy Adults
Karin Amrein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Sclerostin levels during growth in children
S. Kirmani et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
Ulrike I. Moedder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men
Elaine W. Yu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Asiri R. Wijenayaka et al.
PLOS ONE (2011)
Immature Osteoblast Lineage Cells Increase Osteoclastogenesis in Osteogenesis Imperfecta Murine
Haitao Li et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls
A. H. van Lierop et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Matthew T. Drake et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Faryal S. Mirza et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Control of the SOST bone enhancer by PTH using MEF2 transcription factors
Olivier Leupin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography
RP Crawford et al.
BONE (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Static and dynamic bone histomorphometry in children with osteogenesis imperfecta
F Rauch et al.
BONE (2000)
Share Paper
